Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients Publication Population Pharmacokinetic/Pharmacodynamic Modeling for the Time Course of Tumor Shrinkage by Motesanib in Thyroid Cancer Patients To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response…Certara2010年11月1日
Determination of a Quantitative Relationship Between Hepatic CYP3A5*1/*3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations Publication Determination of a Quantitative Relationship Between Hepatic CYP3A5*1/*3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations The creation of virtual populations allows the estimation of pharmacokinetic parameters, such as metabolic clearance…Certara2010年11月1日
Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening Publication Incorporating Human Dosimetry and Exposure into High-throughput In Vitro Toxicity Screening Many chemicals in commerce today have undergone limited or no safety testing. To reduce the…Certara2010年10月1日
Randomised, Parallel-group, Multicenter, Multinational Phase 2 Study Comparing Edoxaban, an Oral Factor Xa Inhibitor, with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation Publication Randomised, Parallel-group, Multicenter, Multinational Phase 2 Study Comparing Edoxaban, an Oral Factor Xa Inhibitor, with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation The primary objective of this study was to compare the safety of four fixed-dose regimens…Certara2010年9月10日
Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy Publication Mechanistic Toxicokinetic Model for γ-Hydroxybutyric Acid: Inhibition of Active Renal Reabsorption as a Potential Therapeutic Strategy γ-Hydroxybutyric acid (GHB), a drug of abuse, exhibits saturable renal clearance and capacity-limited metabolism. The …Certara2010年9月1日
A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Publication A Pharmacokinetic/Pharmacodynamic Model for Cardiovascular Safety Assessment of R1551 Pharmacokinetic-pharmacodynamic relationships are crucial in understanding a drug's arrhythmogenic potential. Models assist to quantitatively relate…Certara2010年8月21日
A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology Publication A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology Certara2010年7月13日
Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model Publication Confidence Assessment of Predicting Clinical Drug Interactions of Mechanism-based CYP3A Inhibitors Using Simcyp Time-based Approach and a Static Mathematic Model Accurate prediction of the extent of mechanism-based CYP3A inhibition is critical in determining the timing…Certara2010年7月1日
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis Publication Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients…Certara2010年7月1日
What Does Clearance Mean? 技術情報 What Does Clearance Mean? Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…Certara2010年6月13日